Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis

被引:16
作者
Hogan, Julien [1 ]
Godron, Astrid [2 ]
Baudouin, Veronique [1 ]
Kwon, Theresa [1 ]
Harambat, Jerome [2 ]
Deschenes, Georges [1 ]
Niel, Olivier [1 ]
机构
[1] Robert Debre Hosp, AP HP, Pediat Nephrol Dept, Paris, France
[2] Bordeaux Univ, Pediat Nephrol Unit, Pellegrin Enfants Hosp, Bordeaux, France
关键词
Lupus nephritis; Children; Rituximab; Steroid minimization; INTRAVENOUS CYCLOPHOSPHAMIDE; ERYTHEMATOSUS; CHILDREN; EFFICACY; ADOLESCENTS; MANAGEMENT; STEROIDS; DISEASE;
D O I
10.1007/s00467-017-3767-4
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In clinical trials, the addition of rituximab (RTX) to the combination therapeutic regimen of mycophenolate mofetil (MMF) and corticosteroids failed to improve outcome in lupus nephritis (LN). However, recent data suggest that RTX may have steroid-sparing beneficial effects with an efficacy similar to that of conventional regimens. We report our experience with RTX in the treatment of children with LN. Patients treated with RTX for first occurrence of LN class III to V were enrolled in the study. Treatment consisted of methylprednisolone pulse (500 mg/m(2)) followed by RTX (1000 mg/1.73 m(2)) at days 1 and 15, and MMF (1200 mg/m(2)/day). Prednisolone tapering and withdrawal was left to the physician's discretion. Complete remission (CR) was defined as a urine protein-to-creatinine ratio (U Pr/Cr) of < 5 mg/mg and normal serum creatinine, and partial remission (PR) as a U Pr/Cr of < 30 mg/mg and a < 15% rise in serum creatinine over baseline. Twelve patients were included in the study, with median follow-up of 23.7 [interquartile range (IQR) 12.8-33.5] months. Median age of the patients was 13.6 [12.3-15.1] years, median proteinuria was 32 [19-67] mg/mg and median estimated glomerular filtration rate was 76.1 [59.3-97.7] mL/min/1.73 m(2). Median CD20 depletion duration was 10 [6.8-11.0] months. Prednisolone was rapidly tapered, with median dose of 0.3 [0.15-0.41], 0.10 [0.09-0.16] and 0.0 [0.0-0.04] mg/kg/day at 3, 6 and 12 months respectively. At 3 months, three and seven patients achieved CR and PR, respectively; at 6 and 12 months all patients achieved remission (9 CR, 3 PR) and none relapsed during follow-up. Five infectious complications were observed, including three varicella-zoster virus (VZV) infections. In our pediatric patients with LN, therapy with RTX + MMF combined with a rapid decrease in steroid appears to have been an efficacious treatment for severe LN but was associated with high rate of VZV infection. The potential of RTX to allow complete steroid avoidance warrants further investigation in children.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 23 条
  • [1] Alsufyani KA, 2005, J RHEUMATOL, V32, P729
  • [2] Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
    Bertsias, George K.
    Tektonidou, Maria
    Amoura, Zahir
    Aringer, Martin
    Bajema, Ingeborg
    Berden, Jo H. M.
    Boletis, John
    Cervera, Ricard
    Doerner, Thomas
    Doria, Andrea
    Ferrario, Franco
    Floege, Juergen
    Houssiau, Frederic A.
    Ioannidis, John P. A.
    Isenberg, David A.
    Kallenberg, Cees G. M.
    Lightstone, Liz
    Marks, Stephen D.
    Martini, Alberto
    Moroni, Gabriela
    Neumann, Irmgard
    Praga, Manuel
    Schneider, Matthias
    Starra, Argyre
    Tesar, Vladimir
    Vasconcelos, Carlos
    van Vollenhoven, Ronald F.
    Zakharova, Helena
    Haubitz, Marion
    Gordon, Caroline
    Jayne, David
    Boumpas, Dimitrios T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) : 1771 - 1782
  • [3] Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
    Condon, Marie B.
    Ashby, Damien
    Pepper, Ruth J.
    Cook, H. Terence
    Levy, Jeremy B.
    Griffith, Megan
    Cairns, Tom D.
    Lightstone, Liz
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (08) : 1280 - 1286
  • [4] Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
    Dooley, Mary Anne
    Jayne, David
    Ginzler, Ellen M.
    Isenberg, David
    Olsen, Nancy J.
    Wofsy, David
    Eitner, Frank
    Appel, Gerald B.
    Contreras, Gabriel
    Lisk, Laura
    Solomons, Neil
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20) : 1886 - 1895
  • [5] Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ginzler, EM
    Dooley, MA
    Aranow, C
    Kim, MY
    Buyon, J
    Merrill, JT
    Petri, M
    Gilkeson, GS
    Wallace, DJ
    Weisman, MH
    Appel, GB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) : 2219 - 2228
  • [6] Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
    Lehman, TJA
    Onel, K
    [J]. JOURNAL OF PEDIATRICS, 2000, 136 (02) : 243 - 247
  • [7] The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit
    Mackie, F. E.
    Kainer, G.
    Adib, N.
    Boros, C.
    Elliott, E. J.
    Fahy, R.
    Munro, J.
    Murray, K.
    Rosenberg, A.
    Wainstein, B.
    Ziegler, J. B.
    Singh-Grewal, D.
    [J]. LUPUS, 2015, 24 (01) : 66 - 73
  • [8] B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus
    Marks, SD
    Patey, S
    Brogan, PA
    Hasson, N
    Pilkington, C
    Woo, P
    Tullus, K
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (10): : 3168 - 3174
  • [9] Beyond immunosuppression - challenges in the clinical management of lupus nephritis
    Masood, S.
    Jayne, D.
    Karim, Y.
    [J]. LUPUS, 2009, 18 (02) : 106 - 115
  • [10] Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study
    Nikpour, Mandana
    Urowitz, Murray B.
    Ibanez, Dominique
    Harvey, Paula J.
    Gladman, Dafna D.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2011, 13 (05)